Sagimet Biosciences Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 trading plans
Except as set forth below, no director or officer (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as those terms are defined in Item 408 of Regulation S-K) during the quarter ended September 30, 2025.
| ● | On August 21, 2025, George Kemble, our Chairman of the Board, adopted a Rule 10b5-1 trading plan providing for the sale of up to 371,193 shares of Series A common stock vested under outstanding stock options and 75,376 shares of Series A common stock vested under restricted stock units. Mr. Kemble’s Rule 10b5-1 trading plan will remain in effect until the earlier of (i) July 23, 2027; or (ii) the date on which the aggregate 446,569 shares of Series A common stock have been sold under the 10b5-1 trading plan. This trading plan was entered into during an open trading window in accordance with the Company’s policies on insider trading and was intended to satisfy Rule 10b5-1(c). |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.